The FDA SIUU guidance gives pharmaceutical companies a more defined framework for certain firm-initiated scientific communications about unapproved uses. Finalized in January 2025, the guidance addresses how firms may share scientific information with healthcare professionals while maintaining important boundaries between scientific exchange and promotion. For medical affairs, regulatory, legal, and commercial teams, that distinction matters. The challenge is no longer simply deciding whether evidence can be discussed. Instead, companies need an operating model that determines who communicates it, what evidence supports it, how the information is presented, and where promotional activity must stop.
Table of Contents
- What the FDA’s SIUU guidance actually covers
- The line between scientific exchange and promotion
- Why pharma needs a clearer SIUU operating model
- Building a practical SIUU playbook for pharma teams
- Conclusion
- FAQs
What the FDA’s SIUU Guidance Actually Covers
The FDA’s final SIUU guidance focuses on certain firm-initiated communications with healthcare professionals who prescribe or administer medical products to individual patients. Specifically, it addresses scientific information concerning unapproved uses of approved or cleared medical products.
The framework covers several types of source publications. These include published scientific or medical journal articles, clinical practice guidelines, scientific or medical reference texts, and materials from digital clinical practice resources. In addition, firms may provide certain firm-generated presentations of scientific information when those presentations accompany qualifying source publications.
However, the policy is not a general authorization for off-label promotion. FDA states that when communications are consistent with the guidance’s recommendations, the agency does not intend to use the dissemination of that communication, standing alone, as evidence of a new intended use. That distinction is critical.
Moreover, FDA does not expect firms to submit qualifying SIUU communications to the agency when they are initially shared with HCPs. Still, communications outside the guidance are not automatically unlawful simply because they do not meet every recommended characteristic.
There is also an important implementation detail. FDA currently identifies the final guidance as “not for current implementation” while awaiting an Office of Management and Budget decision concerning its information-collection provisions. Therefore, organizations should distinguish between the guidance being final and all of its recommendations being currently implementable.
Scientific Exchange Is Not the Same as Promotion
For pharma teams, the central issue is context. Scientific information does not become nonpromotional simply because it includes citations, data, or medical terminology. Rather, the source, presentation, audience, disclosures, and surrounding communications all matter.
FDA’s SIUU framework puts considerable emphasis on the quality and independence of scientific source materials. Consequently, firms should evaluate whether publications are scientifically sound and provide enough context for HCPs to assess the evidence. Communications should also clearly identify that the discussed use has not been approved or cleared by FDA.
Furthermore, firm-generated presentations should remain faithful to the underlying source publication. Selectively highlighting favorable outcomes while minimizing limitations could change how an otherwise scientific communication is perceived.
That issue becomes especially important as scientific content moves across digital channels. A medical affairs presentation, an HCP portal, a sales interaction, and a digital campaign can reach similar audiences while serving very different purposes.
As a result, channel governance matters almost as much as content governance. Pharma organizations developing broader HCP engagement strategies should consider how scientific communications fit alongside their overall pharmaceutical marketing activities without allowing the two functions to blur.
Why Pharma Needs a Clearer SIUU Operating Model
The practical impact of the FDA’s SIUU guidance extends well beyond regulatory affairs. Medical, legal, compliance, communications, and commercial leaders all need to understand where their responsibilities begin and end.
First, companies should define which teams may initiate or distribute SIUU communications. Clear ownership reduces the chance that scientific materials will migrate into promotional channels without appropriate review.
Second, organizations need a consistent process for evaluating source publications. The fact that a study is published does not automatically make it suitable for an SIUU communication. Therefore, teams should consider scientific validity, relevance, limitations, and whether the publication provides the balanced context an HCP needs.
Third, review processes should account for the presentation itself. Headlines, summaries, graphics, data visualizations, hyperlinks, and calls to action can all influence how information is interpreted. A scientifically accurate chart can still create a misleading impression when stripped of important context.
In addition, digital distribution makes these boundaries harder to manage. Content can be copied, forwarded, repurposed, or placed next to promotional material. Organizations working with digital health media and HCP audiences should therefore build compliance considerations into channel design rather than treating review as the final step. Resources from eHealthcare Solutions also illustrate how specialized digital environments can connect healthcare brands with professional audiences.
Ultimately, the strongest model is cross-functional. Medical affairs brings scientific expertise, regulatory and legal teams interpret requirements, and commercial teams need clear rules for what they can and cannot do.
Building a Practical SIUU Playbook for Pharma Teams
A useful SIUU playbook should turn regulatory principles into repeatable decisions. Instead of asking teams to interpret the guidance from scratch every time new evidence appears, companies can establish defined pathways for evidence review, content development, approval, distribution, and monitoring.
For example, the process can identify acceptable source types and required disclosures before content development begins. It can also establish rules governing firm-generated summaries, visual presentations, and digital distribution.
Training is equally important. Commercial employees do not need to become regulatory lawyers, but they should recognize when a scientific discussion crosses into an area requiring medical or regulatory involvement. Likewise, medical teams should understand how the placement or reuse of their content could alter its context.
Companies should also document decisions. Emerging clinical evidence can move quickly, particularly around congress presentations, new publications, and changing standards of care. Therefore, a documented review trail can help teams explain why a particular communication was approved and how its use was limited.
Meanwhile, leaders should monitor FDA updates before changing established practices. The agency’s Office of Prescription Drug Promotion remains an important resource for regulatory information involving prescription drug promotion.
The goal is not to eliminate scientific exchange. Rather, it is to create a system in which useful scientific information can reach HCPs without turning uncertainty about emerging evidence into promotional risk.
Conclusion
FDA’s final SIUU guidance gives pharma companies a clearer view of the agency’s enforcement policy for certain scientific communications about unapproved uses. Yet it does not erase the boundary between scientific exchange and promotion.
For pharmaceutical organizations, the opportunity lies in building stronger governance around evidence, disclosures, presentation, channel selection, and team responsibilities. Moreover, companies should keep the guidance’s current implementation status in mind and monitor FDA updates.
A well-designed SIUU playbook can help medical, regulatory, legal, communications, and commercial teams work from the same rules. In a fast-moving evidence environment, that alignment may be just as important as the content itself.
FAQs
What is the FDA’s SIUU guidance?
It is FDA guidance describing the agency’s enforcement policy for certain firm-initiated communications to HCPs involving scientific information on unapproved uses of approved or cleared medical products.
Does SIUU guidance allow pharmaceutical companies to promote off-label uses?
No. The guidance addresses specified scientific communications and does not provide a general authorization for off-label promotion.
What types of scientific sources can SIUU communications include?
The guidance addresses qualifying journal articles, clinical practice guidelines, scientific or medical reference texts, digital clinical practice resources, and certain firm-generated presentations accompanying source publications.
Is the final SIUU guidance currently implemented?
FDA lists the January 2025 guidance as final but “not for current implementation” pending an OMB decision concerning the collection of information described in the guidance.
Why should commercial teams understand SIUU rules?
Scientific and promotional activities can intersect across HCP channels. Clear roles, escalation procedures, and content controls can help prevent scientific communications from being repurposed in ways that create promotional concerns.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
